Position in EXEL
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$716,797
+$173,596 QoQ
Shares Held
13,174
+4.0% QoQ
Ownership
0.005%
of shares outstanding
% of Portfolio
0.01%
of 13F equity value
Holder Rank
#381
of 754 holders
Holding Since
Sep 2025
4 quarters on record
Voting authority
Sole 2%
Shared 0%
None 98%
Common Shares in EXEL Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026Waverly Advisors, LLC holds $25,407,818 across 23 Biotechnology names. EXEL ranks #8 (2.8% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
23,131 | $11,489,861 | |
| 2 | REGN |
Regeneron Pharmaceuticals, Inc.
|
5,584 | $3,481,847 | |
| 3 | SYRE |
Spyre Therapeutics, Inc.
|
25,512 | $2,264,955 | |
| 4 | VKTX |
Viking Therapeutics, Inc.
|
37,026 | $1,444,384 | |
| 5 | EYPT |
EyePoint, Inc.
|
77,914 | $1,114,170 | |
| 6 | CRSP |
CRISPR Therapeutics AG
|
18,163 | $990,610 | |
| 7 | INCY |
Incyte Corp
|
8,628 | $978,070 | |
| 8 | EXEL |
Exelixis, Inc.
This page
|
13,174 | $716,797 |
All Filings in EXEL
Export CSV
4 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $716,797 | 13,174 | Shares | Sole | 2026-08-14 | |
| 2026-03-31 | $543,201 | 12,665 | Shares | Sole | 2026-05-15 | |
| 2025-12-31 | $579,169 | 13,214 | Shares | Sole | 2026-02-17 | |
| 2025-09-30 | $330,523 | 8,003 | Shares | Sole | 2025-11-14 | |
| No filing history on record for this holder in this stock. | ||||||